Biktarvy

Biktarvy produced by Lucius Pharmaceuticals is a highly effective triple-combination antiretroviral drug. It features convenient administration and good tolerability, providing a cost-effective once-daily treatment option for patients infected with HIV-1.

Brief Summary of Important Information About Biktarvy.

Active Ingredients

Its main active ingredients are bictegravir, emtricitabine, and tenofovir alafenamide.

Target Population

It is indicated for adult patients and pediatric patients (with a body weight of at least 14 kg) infected with HIV-1.

Dosage and Administration

It is usually taken orally once daily, one tablet each time, either with food or on an empty stomach. The specific dosage needs to be adjusted according to the patient’s body weight and renal function. Reference article: Dosage and Administration of Biktarvy

Use in Special Populations

Pregnant women, patients with renal impairment, and patients with hepatic impairment need to have their medication adjusted or undergo enhanced monitoring under the guidance of a doctor.

Drug Overdose

In case of drug overdose, seek medical attention immediately. Symptomatic and supportive treatments should be administered, and hemodialysis may be used to remove some components if necessary.

Storage

The medicine should be stored in its original packaging, protected from high temperature and high humidity, and placed out of the reach of children.

Pharmacokinetics

Pharmacokinetic data show that the absorption of its ingredients is stable. It can be taken with food or on an empty stomach, and food has little impact on the overall absorption.

FDA，2025.07